



# Result of General Meeting

June 8, 2023

RNS Number : 1562C

Renalytix PLC

08 June 2023

## Renalytix plc ("Renalytix" or the "Company")

### Result of General Meeting

**LONDON and SALT LAKE CITY, June 8, 2023** -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting ("GM") held earlier today all resolutions were passed. Further details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 11 May 2023.

The results of the GM are detailed below:

Resolution	In Favour Votes	%	Against Votes	%	Withheld Votes
1	35,540,650	98.8%	439,984	1.2%	62,458
2	35,509,132	98.7%	471,662	1.3%	62,298

### *For further information, please contact:*

**Renalytix plc**  
James McCullough, CEO

[www.renalytix.com](http://www.renalytix.com)  
Via Walbrook PR

**Stifel (Nominated Adviser, Joint Broker)**  
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea

Tel: 020 7710 7600

**Investec Bank plc (Joint Broker)**  
Gary Clarence / Shalin Bhamra

Tel: 020 7597 4000

**Walbrook PR Limited**  
Paul McManus / Alice Woodings / Lianne Applegarth

Tel: 020 7933 8780 or [renalytix@walbrookpr.com](mailto:renalytix@walbrookpr.com)  
Mob: 07980 541 893 / 07407 804 654 / 07584 391 303

**CapComm Partners**  
Peter DeNardo

Tel: 415-389-6400 or [investors@renalytix.com](mailto:investors@renalytix.com)

### **About Renalytix**

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit [www.renalytix.com](http://www.renalytix.com).

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [rns@lseg.com](mailto:rns@lseg.com) or visit [www.rns.com](http://www.rns.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

ROMEALKPEALDEFA